Origin applies to China regulatory agency for clinical pathway classification
PRINCETON, New Jersey, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that it had applied to NMPA (formerly CFDA) for classification of its plasma-generated nitric oxide device for the …